We are live on ! Find out more
DNTH icon

Dianthus Therapeutics
DNTH

90 hedge funds and large institutions have $418M invested in Dianthus Therapeutics in 2021 Q1 according to their latest regulatory filings, with 12 funds opening new positions, 26 increasing their positions, 29 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

306% more call options, than puts

Call options by funds: $739K | Put options by funds: $182K

64% more capital invested

Capital invested by funds: $255M → $418M (+$163M)

0.34% more ownership

Funds ownership: 4.21% → 4.55% (+0.34%)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

2% less funds holding

Funds holding: 92 → 90 (-2)

10% less repeat investments, than reductions

Existing positions increased: 26 | Existing positions reduced: 29

14% less first-time investments, than exits

New positions opened: 12 | Existing positions closed: 14

Holders
90
Holders Change
-2
Holders Change %
-2.17%
% of All Funds
1.58%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.04%
New
12
Increased
26
Reduced
29
Closed
14
Calls
$739K
Puts
$182K
Net Calls
+$557K
Net Calls Change
+$675K

Top Buyers

1
O
OrbiMed
New York
+$9.98M
2
Citadel Advisors
Citadel Advisors
Florida
+$7.1M
3
CAM
Cormorant Asset Management
Massachusetts
+$6.31M
4
Fidelity Investments
Fidelity Investments
Massachusetts
+$6.05M
5
EC
EcoR1 Capital
California
+$5.85M

Top Sellers

1
EAM
Eventide Asset Management
Massachusetts
-$7.84M
2
Morgan Stanley
Morgan Stanley
New York
-$3.85M
3
Renaissance Technologies
Renaissance Technologies
New York
-$1.68M
4
TCM
Tekla Capital Management
Massachusetts
-$1.51M
5
PM
Prosight Management
Texas
-$985K
Name Holding Trade Value Shares
Change 		Change in
Stake
Wells Fargo
76
Wells Fargo
California
$30K -$164K -975 -86%
Legal & General Group
77
Legal & General Group
United Kingdom
$27K -$2.02K -12 -8%
AIP
78
Ameritas Investment Partners
Nebraska
$20K – – –
UBS Group
79
UBS Group
Switzerland
$17K -$30K -178 -67%
HPC
80
HM Payson & Co
Maine
$17K – – –
BDWM
81
Brewin Dolphin Wealth Management
Ireland
$15.4K +$7.91K +47 +138%
SO
82
STRS Ohio
Ohio
$14K – – –
PCM
83
Penserra Capital Management
California
$12K -$168 -1 -1%
Morgan Stanley
84
Morgan Stanley
New York
$10K -$3.85M -22,870 -100%
Bank of Montreal
85
Bank of Montreal
Ontario, Canada
$8K -$27.4K -163 -81%
AF
86
Advisornet Financial
Minnesota
$1K – – –
Daiwa Securities Group
87
Daiwa Securities Group
Japan
$1K – – –
IFAM
88
Institutional & Family Asset Management
Colorado
$1K – – –
AIG
89
American International Group
New York
$143 +$337 +2 +0.3%
EAM
90
Eventide Asset Management
Massachusetts
– -$7.84M -62,500 Closed
Renaissance Technologies
91
Renaissance Technologies
New York
– -$1.68M -13,388 Closed
TCM
92
Tekla Capital Management
Massachusetts
– -$1.51M -12,027 Closed
PM
93
Prosight Management
Texas
– -$985K -7,853 Closed
Marshall Wace
94
Marshall Wace
United Kingdom
– -$572K -4,563 Closed
BG
95
Bollard Group
Massachusetts
– -$220K -1,750 Closed
AQR Capital Management
96
AQR Capital Management
Connecticut
– -$205K -1,635 Closed
BFM
97
Boothbay Fund Management
New York
– -$123K -978 Closed
CSS
98
Cubist Systematic Strategies
Connecticut
– -$112K -895 Closed
WC
99
Wexford Capital
Florida
– -$44K -352 Closed
Ohio Public Employees Retirement System (OPERS)
100
Ohio Public Employees Retirement System (OPERS)
Ohio
– -$17K -138 Closed
1 2 3
4
5

DNTH Hedge Fund Activity: Q1 2021 in Review

90 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Dianthus Therapeutics (DNTH) for Q1 2021, worth a combined $418M — up 64% from $255M a quarter earlier.

Sellers outnumbered buyers: 14 funds closed out of DNTH and 12 opened new positions — a net loss of 2 holders — while 29 trimmed existing stakes and 26 added.

The largest buyer was OrbiMed, opening a new position worth an estimated $9.98M. The largest seller was Eventide Asset Management, exiting entirely with an estimated $7.84M sold.

  • 90 institutional investors held Dianthus Therapeutics (DNTH) as of Q1 2021, down from 92 in Q4 2020.
  • Funds reported $418M of Dianthus Therapeutics stock for Q1 2021, up 64% quarter-over-quarter.
  • 12 funds opened new Dianthus Therapeutics positions in Q1 2021 and 14 closed out, a net change of -2 holders.
  • The largest Dianthus Therapeutics buyer in Q1 2021 was OrbiMed, an estimated $9.98M added.
  • The largest Dianthus Therapeutics seller in Q1 2021 was Eventide Asset Management, an estimated $7.84M sold.

Based on aggregated 13F filings for Q1 2021.